AgomAb Therapeutics NV (AGMB)
NASDAQ: AGMB · Real-Time Price · USD
13.62
-0.59 (-4.15%)
At close: Mar 6, 2026, 4:00 PM EST
13.53
-0.09 (-0.66%)
After-hours: Mar 6, 2026, 4:02 PM EST
AgomAb Therapeutics NV Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2019 | FY 2018 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 |
| Cost of Revenue | - | - | - | - | 2.89 | 0.39 | |
| Gross Profit | - | - | - | - | -2.89 | -0.39 | |
| Selling, General & Admin | 11.09 | 10.13 | 6.1 | 4.51 | 0.2 | - | |
| Research & Development | 45.74 | 39.31 | 26.31 | 19.42 | - | - | |
| Other Operating Expenses | -2.27 | -1.42 | -1.22 | -1.3 | 0 | - | |
| Operating Expenses | 54.56 | 48.02 | 31.19 | 22.63 | 0.2 | - | |
| Operating Income | -54.56 | -48.02 | -31.19 | -22.63 | -3.09 | -0.39 | |
| Interest Expense | -0.04 | -0.07 | -0.03 | -0.05 | -0.04 | -0 | |
| Interest & Investment Income | 1.5 | 1.22 | 0.25 | 0.07 | 0.03 | - | |
| Currency Exchange Gain (Loss) | -0.23 | -0.23 | 0.01 | -0.09 | - | - | |
| Other Non Operating Income (Expenses) | -3.54 | 0.84 | 18.96 | 11.89 | - | - | |
| Pretax Income | -56.87 | -46.26 | -12.01 | -10.81 | -3.1 | -0.39 | |
| Income Tax Expense | 0 | 0 | -0.62 | -2.66 | -0.05 | - | |
| Net Income | -56.88 | -46.27 | -11.39 | -8.14 | -3.05 | -0.39 | |
| Preferred Dividends & Other Adjustments | 15.39 | 11.58 | 7.89 | 5.42 | - | - | |
| Net Income to Common | -72.27 | -57.85 | -19.28 | -13.56 | -3.05 | -0.39 | |
| Shares Outstanding (Basic) | 0 | 0 | 0 | 0 | - | - | |
| Shares Outstanding (Diluted) | 0 | 0 | 0 | 0 | - | - | |
| EPS (Basic) | -2890.60 | -2314.04 | -771.28 | -542.56 | - | - | |
| EPS (Diluted) | -2890.60 | -2314.04 | -771.28 | -542.56 | - | - | |
| Free Cash Flow | -51.37 | -47.5 | -24.59 | -18.97 | - | - | |
| Free Cash Flow Per Share | -2054.80 | -1900.12 | -983.68 | -758.68 | - | - | |
| EBITDA | -54.43 | -47.97 | -31.09 | -22.61 | - | - | |
| D&A For EBITDA | 0.13 | 0.06 | 0.1 | 0.02 | - | - | |
| EBIT | -54.56 | -48.02 | -31.19 | -22.63 | -3.09 | -0.39 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.